[1]颜晶,综述,常静,等.半乳糖凝集素3在心肌梗死中的研究进展[J].心血管病学进展,2016,(2):129-132.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.008]
　YAN Jing,CHANG Jing.Research Advances in the Role of Galectin-3 in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(2):129-132.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.008]
点击复制

半乳糖凝集素3在心肌梗死中的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年2期
页码:
129-132
栏目:
综述
出版日期:
2016-04-20

文章信息/Info

Title:
Research Advances in the Role of Galectin-3 in Myocardial Infarction
作者:
颜晶; 综述; 常静; 审校
重庆医科大学附属第一医院心内科,重庆 400016
Author(s):
YAN Jing;  CHANG Jing
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
关键词:
半乳糖凝集素3;  心肌梗死;  心脏重塑;  心肌纤维化
Keywords:
Galectin-3;  Myocardial infarction;  Cardiac remodeling;  Myocardial fibrosis
分类号:
R542.2
DOI:
10.16806/j.cnki.issn.1004-3934.2016.02.008
文献标志码:
A
摘要:
半乳糖凝集素3作为一种炎症相关因子参与细胞的凋亡、增殖及再生。近年来,研究发现其在心肌梗死后心脏重塑方面亦发挥重要作用,两者有着密切的联系,现就半乳糖凝集素3作为一种心肌梗死后心肌纤维化的标志物的研究进展做一综述。
Abstract:
As an inflammatory factor,galectin-3 is involved in the process of cell apoptosis,proliferation and regeneration.Recent studies have found that galectin-3 plays an important role in cardiac remodeling after myocardial infarction and that both have a close relationship.We reviewed the research progress of galectin-3 as a marker of myocardial fibrosis after myocardial infarction in this article.

参考文献/References:

[1] de Boer RA,Voors AA,Muntendam P,et al.Galectin-3: a novel mediator of heart failure development and progression[J].Eur J Heart Fail,2009,11(9):811-817.
[2] Dumic J, Dabelic S, Flogel M.Galectin-3:an open-ended story[J].Biochim Biophys Acta,2006,1760(4):616-635.
[3] Yu L,uifrok WPR,Meissner M,et al.Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail,2013,6(1):107-117.
[4] Sharma UC,Pokharel S,van Brakel TJ,et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation,2004,110(19):3121-3128.
[5] Ho JE,Liu C,Lyass A,et al.Galectin-3: a marker of cardiac fibrosis,predicts incident heart failure in the community[J].J Am Coll Cardiol,2012,60(14):1249-1256
[6] Calvier L, Miana M,Reboul P,et al.Galectin-3 mediates aldosterone-induced vascular fibrosis[J].Arterioscler Thromb Vasc Biol,2013,33(1):67-75.
[7] Menini S,Iacobini C,Ricci C,et al.The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis[J].Cardiovasc Res,2013,100(3):472-480.
[8] Henderson NC,Mackinnon AC,Farnworth SL,et al.Galectin-3 regulates myofibroblast activation and hepatic fibrosis[J].Proc Natl Acad Sci USA,2006,103(13):5060-5065.
[9] Henderson NC,Mackinnon AC,Farnworth SL,et al.Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis[J].Am J Pathol,2008,172(2):288-298.
[10] Farnworth SL,Henderson NC,Mackinnon AC,et al.Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function[J].Am J Pathol,2008,172(2):395-405.
[11] Mackinnon AC,Gibbons MA,Farnworth SL,et al.Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3[J].Am J Respir Crit Care Med, 2012,185(5):537-546.
[12] Sanchez-Mas J,Lax A,Asensio-Lopez MC,et al.Galectin-3 expression in cardiac remodeling after myocardial infarction[J].Int J Cardiol,2014,172(1):e98-e101.
[13] Hashmi S,Al-Salam S.Galectin-3 is expressed in the myocardium very early post-myocardial infarction[J].Cardiovasc Pathol,2014,24(4):213-223.
[14] Gonzalez GE,Cassaglia P,Noli Truant S,et al.Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice[J].Int J Cardiol,2014,176(3):1423-1425.
[15] Mayr A,Klug G,Mair J,et al.Galectin-3:relation to infarct scar and left ventricular function after myocardial infarction[J].Int J Cardiol,2013,163(3):335-337.
[16] Weir RA,Petrie CJ,Murphy CA,et al.Galectin-3 and cardiac function in survivors of acute myocardial infarction[J].Circ Heart Fail,2013,6(3):492-498.
[17] Szadkowska I,Wlazel RN,Migala M,et al.The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty[J].Cardiol J,2013,20(6):577-582.
[18] Tsai TH,Sung PH,Chang LT,et al.Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention[J].J Atheroscler Thromb,2012,19(12):1073-1082.
[19] Tuñón J,Blanco-Colio L,Cristóbal C,et al.Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease[J].Am J Cardiol, 2014,113(3):434-440.
[20] Maisel A,Xue Y,van Veldhuisen DJ,et al.Effect of spironolactone on 30-day death and heart failure rehospitalization(from the COACH study)[J].Am J Cardiol,2014,114(5):737-742.
[21] Calvier L,Martinez-Martinez E,Miana M,et al.The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries[J].JACC Heart Fail,2015,3(1):59-67.
[22] Lax A,Sanchez-Mas J,Asensio-Lopez MC,et al.Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction[J].JACC Heart Fail,2014,3(1):50-58.
[23] Liu YH,DAmbrosio M,Liao TD,et al.N-acetyl-seryl-aspartyl-lysyl-prolineprevents cardiac remodeling and dysfunction induced by galectin-3,a mammalian adhesion/growth-regulatory lectin[J].Am J Physiol Heart Circ Physiol,2009,296(2):404-412.
[24] Kolatsi-Joannou M,Price KL,Winyard PJ,et al.Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury[J].PLoS One,2011,6(4):e18683.
[25] Frenay AR,Yu L,van der Velde AR,et al.Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy[J].Am J Physiol Renal Physiol,2015,308(5):500-509.

相似文献/References:

[1]宋菲,综述,俞梦越,等.干细胞来源的外泌体:心肌梗死治疗新启示[J].心血管病学进展,2016,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.007]
　SONG Fei,YU Mengyue.Exosomes Derived from Stem Cells: Novel Approach in Treatment of Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.007]
[2]许利冬,综述,李为民,等.左主干解剖形态与左冠状动脉粥样硬化研究新进展[J].心血管病学进展,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
　XU Lidong,LI Weimin.New Progress Between Left Main Coronary Anatomy and Left Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
[3]刘如晨,综述,徐争鸣,等.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2016,(3):240.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.006]
　LIU Ruchen,XU Zhengming,LI Tianchang.Thrombus Aspiration in the Treatment of Acute ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(2):240.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.006]
[4]王艳,综述,石蓓,等.心脏干细胞修复梗死心肌作用机制的研究进展[J].心血管病学进展,2016,(3):315.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.027]
　WANG Yan,SHI Bei.Research Progress of Cardiac Stem Cells Repairing Infarction Myocardial Function Mechanism[J].Advances in Cardiovascular Diseases,2016,(2):315.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.027]
[5]施晶晶,陶以嘉,徐大立.室性期前收缩形态诊断心肌梗死[J].心血管病学进展,2015,(5):655.[doi:10.3969/j.issn.1004-3934.2015.05.034]
　SHI Jingjing,TAO Yijia,XU Dali.Diagnosis of Myocardial Infarction by Ventricular Premature Beats[J].Advances in Cardiovascular Diseases,2015,(2):655.[doi:10.3969/j.issn.1004-3934.2015.05.034]

备注/Memo

备注/Memo:
作者简介:颜晶(1980—),在读硕士,主要从事心血管疾病临床研究。Email: cgyanjing@126.com 通信作者:常静(1969—),教授,博士,主要从事冠心病方面的临床研究。Email: chang8753@aliyun.com
更新日期/Last Update: 2016-03-25